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Helen Ollendorff-Curth (Fig. 1) was one of the ﬁrst female pio-
neers in academic dermatology and the study of genodermatoses,
and her research contributions continue to resonate today. Born in
1899 into a successful Jewish family in Breslau, Germany (now
Wroclaw, Poland), she grew up under the guidance of her mother,
Paula, a women’s advocate in her own right. Paula was an elected
city councilor and social advocate who worked to establish support-
ive housing for single women and victims of domestic abuse
(Burgdorf and Hoenig, 2013).
Ollendorff-Curth’s early life was not without hardship. She lost
her father at a young age and, tragically, only two of her three siblings
lived to adulthood. Nevertheless, determined to pursue a career in
medicine, Ollendorff-Curth ﬂourishedwhile attending several presti-
gious German universities, rotating in Breslau, Freiburg, and Munich.
This was an extraordinary accomplishment given that shewas a Jew-
ish woman, a demographic that was part of an extreme minority in
the profession at the time (Burgdorf and Hoenig, 2013; Burgdorf
and Scholz, 2004).
When she graduated from medical school in 1923 (Bader
and Shipman, 2015), the rise of the Third Reich and the dawn of
World War II proved to be pivotal in Ollendorff’s career. Growing
anti-Semitism in Germany catalyzed her immigration to the United
States where she, along with her husband, Rudolf Wilhelm
Paul Curth, would form a longstanding professional relationship
with Columbia University (Burgdorf and Hoenig, 2013; Burgdorf
and Scholz, 2004).
Of particular interest, Ollendorff-Curth lent both her maiden and
married names to four distinct eponymous entities still in use in aca-
demic dermatology. First, the Ollendorff probe sign refers to the ex-
quisite tenderness of papules found on the palms, plantar surfaces,
face, ﬂexural surfaces, and trunk of patients with secondary syphilis
when touched gently during an examination probe (James et al.,
2011). The probe sign, which helps distinguish syphilitic from non-
syphilitic lesions, was originally published as a component of
Ollendorff-Curth’s medical school thesis, which earned her top
honors (Burgdorf and Scholz, 2004). Later in her career and before
emigrating from Germany, Ollendorff-Curth—as she was known
after her marriage—would further deﬁne the “Curth criteria” in her
seminal work on acanthosis nigricans for the diagnosis of
paraneoplastic dermatoses. The “Curth criteria”were deﬁned as con-
current onset with primary neoplasm, parallel development/resolu-
tion with primary neoplasm, speciﬁcity between tumor type and
cutaneous eruption type, and signiﬁcant statistical and genetic asso-
ciation between dermatosis and malignancy (Bader and Shipman,
2015; Thiers et al., 2009). During this time, she also provided keyhttp://dx.doi.org/10.1016/j.ijwd.2016.06.002
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differences in disease course and age of onset between the benign
and malignant forms of dermatosis. Benign is often early-onset and
genetically-determined, while the malignant form is associated
with underlying neoplasm (Curth, 1952).
Ollendorff-Curth also earned the distinction of being eponymously
commemorated in two separate genodermatoses: Buschke-Ollendorff
Syndrome (BOS) under her maiden name, and Ichthyosis hystrix,
Curth-Macklin (IHCM) type under her married name (Burgdorf and
Hoenig, 2013). The current article provides an update on these two
conditions and shows how modern genetic analysis of affected pa-
tients has both improved our understanding of thedisease pathophys-
iology and honored the legacy of one of the ﬁrst female leaders of
academic dermatology.
Buschke-Ollendorff Syndrome
After studying in multiple universities in Germany and earning
her medical degree, Ollendorff-Curth moved to Berlin in 1924 and
further cultivated her academic career under the tutelage of Abraham
Buschke, an internationally renowned professor of dermatology
(Burgdorf and Scholz, 2004). Under his mentorship, Ollendorff-
Curth ﬁrst described and deﬁned disseminated dermatoﬁbrosis
lenticularis, later known as BOS, in 1928 (Burgdorf and Hoenig,
2013; Burgdorf and Scholz, 2004; Woodrow et al., 2001).
BOS is a rare autosomal dominant connective tissue disease, char-
acterized by the formation of elastic and collagenous nevi associated
with a spectrum of osseous ﬁndings (Woodrow et al., 2001). Derma-
tologic ﬁndings include the development of painless, skin-colored,
and often coalescent papules in either an asymmetric or symmetric
distribution (Fig. 2). Histological analysis characteristically reveals
an increased volume of large, interlacing elastin ﬁbrils (Yadegari
et al., 2010). Associated osseous ﬁndings vary and typically increase
with age. A common associatedmanifestation is osteopoikilosis, a be-
nign sclerosing bone dysplasia that appears as multiple, well-
circumscribed, ovoid opacities seen on plain radiographs of the
epiphyses and metaphyses of long bones and the pelvis, and
trabeculated small bones of the distal extremities (Fig. 3) (Roberts
et al., 1993). These bone islands are small foci of dense remodeled
cortical bone with a lamellar structure (Lagier et al., 1984). Some pa-
tients may present with melorheostosis, a sclerosing bone dysplasia
stemming from abnormal angiogenesis and bone proliferation that
characteristically appears as an irregular exophytic cortical hyperos-
tosis resembling dripping candle wax on plain radiography (Fig. 4)
(Bansal, 2008). Unlike osteopoikilosis, which is typically an asymp-
tomatic incidental ﬁnding, melorheostosis is often painful and may
result in severe joint contractures (Gutierrez et al., 2015). Somematologic Society. This is an open access article under the CC BY-NC-ND license
Fig. 1. Helen Ollendorff-Curth. Reprinted from Burgdorf and Scholz (2004), with per-
mission from Elsevier. Fig. 3. Osteopoikilosis, a benign sclerosing bone dysplasia, affecting the lumbar spine
and pelvis.
109Editorialauthors have reported additional, although less frequent, skeletal
manifestations of BOS, including otosclerosis (Pope et al., 2016;
Schnur et al., 1994), congenital spinal stenosis (Pope et al., 2016;
Schnur et al., 1994), scoliosis (Pope et al., 2016), and craniosynostosis
(Reid et al., 2008).
Recent genome-wide linkage analysis studies showed the under-
lying pathogenesis of the dermatologic and skeletal ﬁndings original-
ly described by Ollendorff. BOS is an autosomal dominant disease,
described in several series in the literature as recurring in families
(Hellemans et al., 2004; Kawamura et al., 2005; Yadegari et al.,
2010; Zhang et al., 2009). The causative mutation is believed to be
in the gene encoding the LEM domain-containing protein 3
(LEMD3), an inner nuclear membrane protein, which, via interac-
tions through Smad proteins, plays a key role in the regulation of
transforming growth factor beta (TGF-β) andbonemorphogenic pro-
tein (Hellemans et al., 2004; Zhang et al., 2009). Abnormal function of
mutant LEMD3 leads to unmitigated TGF-β signaling and consequent
increased steady-state levels of elastin messenger RNA (mRNA) and
elastin accumulation in the dermis (Woodrow et al., 2001). Of note,
increased TGF-β signaling has also been associatedwith otherﬁbrotic
skin disorders (Hellemans et al., 2004; Saito et al., 2001; Mori et al.,
2003) and hypertrophic scarring (Korekawa et al., 2012). The skeletal
ﬁndings in BOSmay be directly attributed to loss of LEMD3 function,Fig. 2. Painless, skin-colored, coalescent papules characteristic of Buschke-Ollendorff
syndrome.as increased activity of both bone morphogenic protein and TGF-β
have been implicated in increased bone formation in a variety of scle-
rosing bone disorders (de Vernejoul and Kornak, 2010; Hellemans
et al., 2004). To date, 125 pathogenic mutations of the LEMD3 gene
have been detected (Kratzsch et al., 2016), which cause the skeletal
and dermatologic ﬁndings often encountered in BOS through a mul-
titude of different mechanisms, including nonsense-mediated decay
of LEMD3 mRNA (Burger et al., 2010) and nonsense-mediated oblit-
eration of the functional domains of the protein (Yuste-Chaves
et al., 2011).
In themajority of cases, no speciﬁc treatment is indicated because
the skin papules are often small and painless (Pope et al., 2016).
There is also no signiﬁcant increase in mortality. However, early
and accurate diagnosis of BOS in patients with concomitant elastic
nevi and benign osteopoikilosis is paramount in avoiding unneces-
sary workup and patient anxiety for the incidental discovery of
bone islands, whichmay appear as sclerotic neoplastic disease.More-
over, in patients diagnosed with melorheostosis, active painFig. 4.Melorheostosis involving the ulnar aspect of the third proximal phalanx. Note
that it takes on the appearance of dripping candle wax.
Fig. 5.HelenOllendorff-Curth and RudolfWilhelmPaul Curth. Reprinted fromBurgdorf
and Scholz (2004), with permission from Elsevier.
Fig. 7. Severe palmoplantar keratoderma often seen in Ichthyosis hystrix, Curth-
Macklin type. Photo courtesy Leslie Castelo-Soccio, MD, PhD. Children’s Hospital of
Philadelphia.
110 Editorialmanagement, bisphosphonate administration, and surgical correc-
tion may be indicated in the most severe cases (Moulder and
Marsh, 2006; Slimani et al., 2013; Takashima et al., 2016).
Ichthyosis Hystrix, Curth-Macklin Type
While ﬂourishing under Buschke’s mentorship, Ollendorff-Curth
met fellow dermatologist Rudolf Wilhelm Paul Curth, who joined
the department in 1925. Their relationship rapidly evolved from a
professional collaboration to friendship and ﬁnally to love, and they
were married on New Year’s Eve in 1927 (Fig. 5) (Burgdorf and
Scholz, 2004). The couple immigrated to the United States in 1931Fig. 6.Madge Thurlow Macklin (center). Acc. 90-105 - Science Serwhere they opened a medical practice in New York City and formed
a long-standing association with Columbia University (Burgdorf and
Hoenig, 2013; Burgdorf and Scholz, 2004). Ollendorff-Curth contin-
ued her landmark work in the study of genodermatoses and began
collaborating in 1954 with fellow female academic medical geneti-
cist, Madge Thurlow Macklin (Fig. 6). A luminary in her own right
who originally coined the term medical genetics, Macklin conducted
compelling research on the contribution of genetic factors to the de-
velopment of many diseases, such as cancer and mental illness, and
advocated strongly for the inclusion of genetics studies in medical
school curricula (Comfort, 2006).
In 1954, Ollendorff-Curth andMacklin played a pivotal role in the
ﬁrst description of a form of ichthyosis hystrix (Bader and Shipman,
2015; Ollendorff-Curth et al., 1972). Referred to as IHCM, this ex-
tremely rare genodermatosis has the unique distinction of being
one of the ﬁrst syndromes named after two women (Burgdorf and
Hoenig, 2013; Burgdorf and Scholz, 2004). Different clinical variants
of Ichthyosis hystrix, characterized by bilateral, widespread develop-
ment of gray-dark brown, hyperkeratotic verrucae, scales, and
plaques, have been recognized in the literature (Fig. 7) (James et al.,
2011; Mehta et al., 2015). In IHCM, hyperkeratotic plaques may coa-
lesce over ﬂexor and extensor surfaces, including palmar and plantarvice, Records, 1920s-1970s, Smithsonian Institution Archives.
111Editorialsurfaces, causing painful, bleeding ﬁssures. Unlike epidermolytic hy-
perkeratosis, a similar condition, lesions in IHCM do not demonstrate
erythroderma, skin fragility, or blistering (Mehta et al., 2015). Light
microscopy of involved skin demonstrates keratin intermediate ﬁla-
ments aggregated into continuous peripheral shells, perinuclear vac-
uoles, and binuclear keratinocytes. Electron microscopy, however,
shows no keratin clumping, suggesting that expression of abnormal
keratin plays a central role in pathogenesis (Niemi et al., 1990;
Sprecher et al., 2001).
Although sporadic cases have been reported in the literature
(Mehta et al., 2015; Yusuf et al., 2009; Brusasco et al., 1994), IHCM
is typically described using Ollendorff-Curth’s original description
(Ollendorff-Curth et al., 1972) as an autosomal dominant condition
recurring in two families (Niemi et al., 1990; Sprecher et al., 2001).
More recent genetic linkage studies have revealed that variousmuta-
tions in the KRT1 gene, which encodes keratin 1, play a central role in
disease pathogenesis (Fonseca et al., 2013; Ishida-Yamamoto et al.,
2003; Kubo et al., 2011; Richardson et al., 2006; Sprecher et al.,
2001). Wild-type keratin 1, a component of the intermediate ﬁla-
ment cytoskeleton in the suprabasal epidermis, normally
heterodimerizes via weak hydrophobic and hydrogen bonding inter-
actions with keratin 10 (Richardson et al., 2006) and enables
crosslinking between the corniﬁed cell envelope and the intracellular
matrix to contribute to the barrier integrity of the skin (Roth et al.,
2012). The ability of keratin to dimerize and crosslink is believed to
be dependent on the presence of glycine loops present in the variable
tail domain of keratin 1. Many of the reported mutations implicated
in clinically established IHCM diminish the number of glycine loops
present in the variable tail domain of the translated protein
(Fonseca et al., 2013; Ishida-Yamamoto et al., 2003; Kubo et al.,
2011; Richardson et al., 2006; Sprecher et al., 2001), resulting in ab-
normal interactions between the cell envelope and intracellular ma-
trix. Consequently, this leads to abnormal keratinization and the
clinical phenotype characterized by hyperkeratotic plaques and skin
ﬁssures.
Treatment options for this rare condition are limited. Although
no speciﬁc treatments for IHCM exist, systemic retinoids can be of
limited beneﬁt (Kanerva et al., 1984) but must be prescribed with
caution in children due to the potential risk of skeletal toxicity
(Sethuraman et al., 2016). Topical emollients, calcipotriol ointment,
and liarozole cream appear to result in some therapeutic beneﬁt, but
evaluation of long-term efﬁcacy and safety is needed (Hernandez-
Martin et al., 2013).
Conclusion
Commemorated with four distinct eponyms, Helen Ollendorff-
Curth contributed greatly to the ﬁeld of dermatology and the study
of genodermatoses. In her ﬁnal years, she was diagnosed with
Alzheimer’s dementia and after her death in 1982, her brain was do-
nated to science to study the disease (Burgdorf and Scholz, 2004).
Ollendorff-Curth was survived by her husband, who passed away
from carcinoma of the breast only 2 years later. Their daughter,
Elisabeth Susanne Marie Curth, would go on to graduate from
Smith College and earn a master’s degree from Teachers College at
Columbia University.
Ollendorff-Curth’s impact on academic dermatology remains evi-
dent today. Current genetic studies have shed a powerful light on the
pathogenesis of these conditions and established compelling avenues
for future research to further understand the intricate disease mech-
anisms and help affected patients. Moreover, her legacy continues
after her death through the many distinguished trainees Ollendorff-
Curth inﬂuenced throughout her life, including Drs. Robert W.
Goltz, Robert K. Gorlin, and David R. Bickers. These and countless
other trainees continue to conduct their own groundbreakingresearch and serve as academic leaders, committed educators, and
master clinicians. The legacy of Helen Ollendorff-Curth as one of
dermatology’s ﬁrst and most inﬂuential female academicians will
surely not be forgotten.
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